# A Phase III Trial For Patients With Metastatic Breast Cancer

> **NCT00191152** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 475 (actual)

## Conditions studied

- Breast Cancer
- Breast Neoplasms
- Cancer of the Breast

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** docetaxel
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00191152
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2009-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191152, "A Phase III Trial For Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00191152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*